In a sub-analysis of the ILLUMINATE study, PCSK9 and Lp(a) levels were dose-dependently increased by atorvastatin in patients at high CV risk.
In young asymptomatic individuals with family history of premature ASCVD, elevated Lp(a) is related to higher CAC score, resulting in the identification of individuals with subclinical atherosclerosis.
In type 2 diabetic patients with mixed dyslipidemia on maximal statin therapy, the addition of the PCSK9 inhibitor alirocumab is more effective than usual care.
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.
In a prospective community-based cohort, Lp(a) ≥50 mg/dL was associated with higher stroke risk in those without AF, but not in those with AF, nor with an elevated risk of AF.
In the CPGS study, OxPL-apoB and OxPL-apo(a) were genetically and observationally associated with CAVD risk and closely correlated with Lp(a) levels.
VBWG ACC 2017 Sotirios Tsimikas summarises the rationale of innovative therapeutic approaches targeting Lp(a), ApoC3 or ATP citric lyase and in what stage of clinical testing they currently are.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
Alirocumab treatment of healthy volunteers reduced LDL-C and LDL-apoB concentrations and doubled the efficiency with which LDL particles were removed from the circulation.
The agreement is for the development and commercialization of novel treatments for lowering lipoprotein(a) and apolipoprotein C-III
Novel antisense oligonucleotides therapy IONIS-APO(a)-L Rx (phase I/II study) results in even more Lp(a) reduction than with IONIS-APO(a) Rx / ISIS-APO(a) Rx therapy.
The consistent reductions in Lp(a) suggest that PCSK9 inhibition with alirocumab, not only effectively lowers LDL-c but also has a substantial and sustained effect on Lp(a).